title: Moving goalposts--regulatory oversight of antibacterial drugs.
abstract: Is uncertainty concerning the regulation of antimicrobial drug trials stifling investment in infectious disease treatments? Here, experts from a large pharma company and a biotech firm provide their perspectives.
authors.affiliation: Wyeth Pharmaceuticals, 500 Arcolo Road, Collegeville, Pennsylvania 19426, USA. brenner1@wyeth.com
authors.forename: Randall
authors.initials: R
authors.lastname: Brenner
authors.forename: Evelyn J
authors.initials: EJ
authors.lastname: Ellis-Grosse
authors.forename: Roger
authors.initials: R
authors.lastname: Echols
mesh_terms: D000900:Anti-Bacterial Agents / Q000096:biosynthesis / Q000138:chemical synthesis; D001709:Biotechnology / Q000331:legislation & jurisprudence*; D002986:Clinical Trials as Topic / Q000592:standards*; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D008826:Microbial Sensitivity Tests / Q000379:methods; D014481:United States
chemical_list: D000900:Anti-Bacterial Agents